Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEO-DUR vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
300-600 mg orally twice daily
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP1A2 and CYP3A4; also by N-acetylation and CYP2E1.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40-60% bound primarily to albumin. Lower in neonates, cirrhotics, and uremic patients.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
Vd: 0.3-0.7 L/kg. Distributes into total body water; higher Vd in neonates (0.6-0.8 L/kg) and with acidosis.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: nearly 100% for immediate-release; extended-release formulations have 90-100% relative bioavailability compared to immediate-release.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%
No data; not applicable.
Child-Pugh A: reduce dose by 50%; Child-Pugh B or C: reduce dose by 75-80%
No data; not applicable.
Initial: 10-20 mg/kg/day orally divided q12h; titrate based on serum levels (therapeutic range 5-15 mcg/m L)
No data; not applicable.
Start at lowest effective dose; monitor serum levels; decrease dose by 25-50% due to reduced clearance
No data; not applicable.
No
None
Risk of serious or fatal cardiovascular adverse events, including seizures and arrhythmias, especially at high doses.,Use with caution in patients with peptic ulcer, seizure disorders, cardiac disease, or hepatic impairment.,Monitor serum theophylline levels to avoid toxicity.,May exacerbate GERD.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component of the formulation.,Concurrent use with ticlopidine or cimetidine (due to significant drug interactions)
Hypersensitivity to arformoterol or any component of the formulation
Food does not significantly affect absorption of sustained-release formulations; however, high-fat meals may slow absorption. Avoid large amounts of caffeine-containing foods/beverages. Charcoal-broiled foods may increase metabolism.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest a possible association with cardiovascular defects and oral clefts, though risk is low. Second and third trimesters: chronic high doses may cause fetal tachycardia and irritability; no structural teratogenicity reported. Overall, FDA Pregnancy Category C; risk vs benefit must be considered.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant exposure via milk is about 1-10% of maternal weight-adjusted dose. May cause irritability or insomnia in neonates. Use with caution, and monitor infant for signs of theophylline toxicity. Breastfeeding is generally considered acceptable if maternal levels are within therapeutic range and infant is observed.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy increases theophylline clearance by approximately 30-50% due to hemodilution and increased hepatic metabolism. Dose may need to be increased by 30-50% to maintain therapeutic levels. Monitor serum concentrations frequently (every 1-2 weeks) and adjust accordingly. After delivery, clearance returns to prepregnancy levels within 2-4 weeks, requiring dose reduction to avoid toxicity.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theo-Dur (theophylline) has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Levels >20 mcg/m L increase toxicity risk. Monitor levels, especially with hepatic impairment, heart failure, or drugs that alter CYP1A2 metabolism (e.g., cimetidine, fluoroquinolones). Avoid use in active seizure disorders unless controlled. Use with caution in peptic ulcer disease.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Do not crush or chew sustained-release tablets; swallow whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, palpitations, seizures.,Keep regular appointments for blood level monitoring.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEO-DUR vs AEROLONE, answered by our medical review team.
THEO-DUR is a Bronchodilator that works by Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEO-DUR and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEO-DUR is: 300-600 mg orally twice daily. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEO-DUR and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEO-DUR is classified as Category C. Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest . AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.